evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

3 questions · 3 findings · 1 reviews · Urology

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 1 · 33.3%Moderate 2 · 66.7%High 0 · 0%

Sunitinib vs avelumab + axitinib (targeted agent versus immunotherapy + targeted agent)

Progression‐free survival · Treatment‐naïve metastatic renal cell carcinoma (clear cell type)

Sunitinib probably leads to higher progression‐free survival(absolute effect size estimates based on… compared with avelumab + axitinib (targeted agent versus immunotherapy + targeted… (moderate certainty).

1 finding from 1 review

Sunitinib vs pembrolizumab + axitinib (targeted agent versus immunotherapy + targeted agent)

Progression‐free survival · Treatment‐naïve metastatic renal cell carcinoma (clear cell type)

Sunitinib probably leads to higher progression‐free survival(absolute effect size estimates based on… compared with pembrolizumab + axitinib (targeted agent versus immunotherapy +… (moderate certainty).

1 finding from 1 review

Sunitinib vs atezolizumab + bevacizumab (targeted agent versus immunotherapy + targeted agent)

Progression‐free survival · Treatment‐naïve metastatic renal cell carcinoma (clear cell type)

Sunitinib may leads to higher progression‐free survival(absolute effect size estimates based on… compared with atezolizumab + bevacizumab (targeted agent versus immunotherapy +… (low certainty).

1 finding from 1 review